An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis

• Egile Nagusiak: Hidehisa Saeki (Egilea), Yukihiro Ohya (Egilea), Naoko Baba (Egilea), Tomomi Imamura (Egilea), Daisuke Yokota (Egilea), Hidetsugu Tsubouchi (Egilea)
• Formatua: Liburua
• Argitaratua: Adis, Springer Healthcare, 2024-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Introduction Difamilast is the first selective phosphodiesterase 4 inhibitor approved for atopic dermatitis (AD) in Japan. A phase 3, 52-week, open-label study is ongoing to establish efficacy and safety of difamilast ointments in infants with AD aged 3 to < 24 months because a clinical...